Shopping Cart
- Remove All
- Your shopping cart is currently empty
JG-231 is a JG-98 analog with anticancer activity.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC).JG-231 inhibits the interaction of Hsp70-BAG3.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC). JG-231 inhibits MDA-MB-231 xenograft tumor model of triple negative breast cancer (TNBC).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $106 | In Stock | |
5 mg | $297 | In Stock | |
10 mg | $388 | In Stock | |
25 mg | $619 | In Stock | |
50 mg | $793 | In Stock | |
100 mg | $1,090 | In Stock | |
500 mg | $2,230 | In Stock |
Description | JG-231 is a JG-98 analog with anticancer activity.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC).JG-231 inhibits the interaction of Hsp70-BAG3.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC). JG-231 inhibits MDA-MB-231 xenograft tumor model of triple negative breast cancer (TNBC). |
In vivo | JG-231 (2, 4 mg/kg; administered intraperitoneally) effectively suppressed the growth of A375, A375-PLX/R, and Colo829 xenografts in athymic nude mice without causing significant body weight loss. JG231-treated tumors exhibited increased lamin A cleavage and p21CIP1 expression. Moreover, JG231-treated tumors also exhibited increased MEK1/2 phosphorylation.[3] |
Molecular Weight | 619.47 |
Formula | C22H18BrCl2N3OS4 |
Cas No. | 1627126-59-3 |
Storage | Shipping with blue ice. | ||||||||||
Solubility Information | DMSO: 1.8 mg/mL (2.9 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.